New patients10% off your first order.

Repair & recovery

When your recovery has stopped keeping up

Soreness that lingers for days, a tendon that never quite settles, a training week that leaves you flat. Here is how HealifyMD approaches slower recovery in midlife, and a frank account of what repair peptides can and cannot claim.

Comprehensive Lab Panel
$199
BPC-157 (compounded)
From $250/month
Wolverine or Repair & Recovery Stack
From $300 to $350/month
FDA-approved peptides here
None

Why recovery slows

Recovery depends on sleep, hormones, nutrition, blood flow and the slow turnover of connective tissue, and most of these shift with age. Deep sleep tends to shorten. Growth hormone and, in men, testosterone gradually decline. Tendons and ligaments remodel more slowly. Many active adults also carry old injuries that flare when training volume rises.

Some causes are easy to miss and very treatable: iron deficiency, low vitamin D, an underactive thyroid, low testosterone, poor sleep from sleep apnea, under-eating relative to training, or a medication side effect. That is why the starting point is a look at your labs and history, not a peptide.

Three ways people start

  • Labs only: the Comprehensive Lab Panel ($199) to check iron, thyroid, hormones, inflammation markers and more, then decide.
  • A single agent: compounded BPC-157 (from $250/month) for a defined trial period with a clear goal.
  • A combination: the Wolverine Stack (BPC-157 with TB-500, from $350/month) or the Repair & Recovery Stack, which adds KPV (from $300/month).

What the repair peptides are

BPC-157 is a short synthetic peptide derived from a protein found in stomach juice. It has been studied mostly in animals for tendon, muscle and gut healing. TB-500 is a fragment related to thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. KPV is a three-amino-acid fragment of alpha-MSH, studied in laboratory and animal models for anti-inflammatory effects.

Sermorelin ODT (from $199/month) is a different kind of agent: a growth hormone–releasing hormone analog that prompts the pituitary to release growth hormone. A sermorelin product was once FDA-approved and later discontinued by its maker; the FDA determined that it was not withdrawn for safety or effectiveness reasons. No sermorelin product is FDA-approved today, and compounded versions are not FDA-approved.

An honest look at the evidence

Most of what is known about BPC-157, TB-500 and KPV comes from animal and cell studies. Human data is limited to small, short studies. When FDA scientists reviewed these peptides for the 2026 advisory meeting, they concluded that the available studies were insufficient to establish safety or effectiveness for the uses reviewed.

No published trial has compared the stacks with their individual ingredients, so we cannot tell you a combination works better than one peptide alone. If you try a repair peptide, your clinician will set a specific goal and timeline and stop it if it does not help.

Where the FDA stands

None of the repair peptides discussed here is FDA-approved for any use. In 2023 the FDA placed a group of peptides, including BPC-157, on its list of bulk substances that raised significant safety concerns for compounding. In April 2026 the agency said it intended to move several of them off that list and asked its Pharmacy Compounding Advisory Committee to review them.

At meetings on July 23 and 24, 2026, the committee narrowly voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, epitalon and semax to the list of substances 503A pharmacies may compound with; it voted against DSIP. FDA staff had recommended against all seven. The votes are advisory only. Until the FDA acts through rulemaking, none of these peptides is on the 503A bulks list, and their status remains under review.

If you still compete

BPC-157 is prohibited under the World Anti-Doping Agency's Prohibited List as a non-approved substance, and other peptides discussed here, including TB-500 and growth hormone–releasing agents, are also classed as doping substances by sports authorities. If you are subject to drug testing in any masters, collegiate or professional sport, tell your clinician before starting anything.

Who should not use repair peptides

  • Anyone pregnant, breastfeeding or trying to conceive.
  • People with active cancer or a history of cancer, because some of these peptides are thought to promote blood vessel growth.
  • Athletes subject to anti-doping testing.
  • Anyone hoping a peptide will replace rehabilitation, imaging or orthopedic care for a significant injury.

The parts of recovery that still matter most

No peptide replaces the basics. Adequate protein, progressive loading under the guidance of a physical therapist when an injury is involved, seven or more hours of sleep and sensible training volume remain the foundation. Your plan will address these alongside any prescription.

Common questions

Do repair peptides actually work?

Animal studies are promising, but human evidence is thin and the FDA has said it is insufficient to establish safety or effectiveness.

Are BPC-157 or TB-500 FDA-approved?

No. Neither is FDA-approved for any use, and as of October 2026 neither is on the FDA's 503A bulks list.

Which option would I be prescribed?

That depends on your labs, history and goal. Many people start with labs and address a deficiency or sleep problem first.

Do I need to stop training?

Usually not, but your clinician or physical therapist may adjust your load while an injury settles.

I compete in a tested sport. Can I use these?

BPC-157 is prohibited under anti-doping rules, and related peptides are also restricted, so discuss this before starting anything.

What happens if it doesn't help?

Your clinician sets a defined trial period, and if there is no meaningful change, the peptide is stopped.

Sources

We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.

  1. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration
  2. FDA Panel Backs 6 Peptides for CompoundingThe American Journal of Managed Care
  3. FDA Signals Potentially Evolving Stance Toward Compounding of Certain PeptidesGoodwin Procter LLP
  4. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C ActU.S. Food and Drug Administration
  5. BPC-157: Experimental Peptide Creates Risk for AthletesU.S. Anti-Doping Agency
  6. Determination That GEREF (Sermorelin Acetate) Products Were Not Withdrawn From Sale for Reasons of Safety or EffectivenessFederal Register (U.S. Food and Drug Administration)

Find out what your body needs next

Start with a free eligibility check. A licensed clinician reviews your history and goals, and recommends labs or treatment only if they fit.

  • No membership fee
  • Licensed clinicians
  • 100% online